Her2 Positive Gastric Cancer clinical trials

Explore recruiting her2 positive gastric cancer clinical trials.

Recruiting her2 positive gastric cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Her2 Positive Gastric Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Multicenter, 2-Arm Randomized, Open-Label Study of Trastuzumab Deruxtecan in Subjects with HER2 Positive Metastatic and/or Unresectable Gastric or Gastro Esophageal Junction (GEJ) Adenocarcinoma Subjects who have Progressed on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Hungary, Portugal, Germany, Spain, Romania, Belgium +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Phase Ⅲ Study of Rilvegostomig in Combination with Fluoropyrimidine and Trastuzumab Deruxtecan versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01).

Netherlands, Hungary, Spain, Germany, France, Austria +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

NeoART – A phase Ib/II platform trial evaluating the safety and activity of neoadjuvant trastuzumab-deruxtecan containing combination therapies for HER2+, resectable esophagogastric adenocarcinoma

Germany, Austria

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma - A phase II trial of the AIO study group – PHERFLOT

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus Or Minus Pembrolizumab as First-Line Treatment in Participants with Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Cancer (DESTINY-Gastric05)

Portugal, Belgium, Germany, Czechia, Italy, Spain +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Master rollover study to provide continued access to, and assess, long term safety of the study drugs.

France, Spain, Belgium, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Her2 Positive Gastric Cancer trials by city

Her2 Positive Gastric Cancer in Toronto Her2 Positive Gastric Cancer in Vancouver Her2 Positive Gastric Cancer in Montreal Her2 Positive Gastric Cancer in Calgary Her2 Positive Gastric Cancer in Edmonton Her2 Positive Gastric Cancer in Ottawa Her2 Positive Gastric Cancer in Winnipeg Her2 Positive Gastric Cancer in Quebec City Her2 Positive Gastric Cancer in Hamilton Her2 Positive Gastric Cancer in Kitchener Her2 Positive Gastric Cancer in London Her2 Positive Gastric Cancer in Halifax Her2 Positive Gastric Cancer in New York Her2 Positive Gastric Cancer in Los Angeles Her2 Positive Gastric Cancer in Chicago Her2 Positive Gastric Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease